Titlebook: Lung Cancer; New Understandings a Anne C. Chiang,Roy S. Herbst Book 2021 Springer Nature Switzerland AG 2021 lung cancer.NSCLC.SCLC.lung ca

遺忘

Ambiguous

Atrium

keloid

努力趕上

Immune Therapy: What Can We Learn From Acquired Resistance?,sponse to these agents can be durable, but most patients will go on to develop resistance after initial tumor regression or prolonged disease stability. In patients with ‘a(chǎn)cquired oligo-resistance,’ in whom progression is limited to two or less disease sites, local therapy may be an effective manage

無力更進

Management of Brain Metastases, brain metastases is increasing. Lung cancer is the most frequent origin of metastases to the brain, and this diagnosis is associated with significant morbidity as well as decreased quality of life and a worse prognosis. The treatment for brain metastases in NSCLC has historically been local therapy

Type-1-Diabetes

Neutral-Spine

COM

Small Cell Lung Cancer: Biology Advances,une checkpoint inhibitors have been approved for use in combination with etoposide plus a platinum agent as initial therapy for patients extensive stage SCLC; with the triplet regimen, the median overall survival is approximately 12?months. Over the past 4?years, several agents, including immune che

使混合